Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Patent
1997-11-21
1999-01-12
Stucker, Jeffrey
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
4242001, 4242081, 4242481, 536 234, 536 2372, 530326, 530327, A61K 3900, A61K 3902, A61K 3800, C07H 2104
Patent
active
058583696
ABSTRACT:
A vaccine containing Mycobacterium bovis BCG which secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of a secretory protein, a carrier, having a signal peptide. BCG constituting the present invention secretes a fusion protein to be obtained by inserting a foreign antigen peptide into the molecular surface of an .alpha.-antigen derived from mycobacteria. Said fusion protein has significantly increased antigenicity and immunogenicity. Therefore, when it is inoculated into animals, it is efficiently recognized by B cells which recognize said antigen, thereby effectively inducing the production of an antibody to said antigen. When said BCG itself is inoculated into animals, it continuously secretes said fusion protein in the bodies of the animals while continuously propagating therein. Therefore, said BCG is an extremely useful vaccine.
Chujo Yoshitomo
Honda Mitsuo
Matsuo Kazuhiro
Tasaka Hiromichi
Yamazaki Akihiro
Ajinomoto Co. Inc.
Japan as represented by Director General of Agency of National I
Park Hankyel T.
Stucker Jeffrey
LandOfFree
Anti-acids secretory recombinant BCG vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-acids secretory recombinant BCG vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-acids secretory recombinant BCG vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1512074